During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US. We asked, What do the initial results from the LOTIS-7 trial suggest for loncastuximab tesirine plus glofitamab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL)?
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Joshua Brody from the Icahn School of Medicine…
During the 18th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub was pleased to speak with Juan Pablo Alderuccio, University of Miami, Florida, US.…
During EHA 2025, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the…
New data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.
On June 18, 2025, the FDA approved tafasitamab in combination with rituximab plus lenalidomide for the treatment of adult patients with R/R FL.
During EHA 2025, the Lymphoma Hub was pleased to speak to Gareth Gregory, Monash University, Melbourne, AU. We asked about the latest updates from the…
Catch up on our live social media coverage of lymphoma and CLL from the 18th International Conference on Malignant Lymphoma.
During EHA 2025, the Lymphoma Hub was pleased to speak to Marek Trněný, Charles University, Prague, CZ, who discussed the significance of the first efficacy…
